Monte Rosa Therapeutics (Monte Rosa Therapeutics) Cash-to-Debt : 5.05 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Monte Rosa Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Monte Rosa Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 5.05.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Monte Rosa Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Monte Rosa Therapeutics's Cash-to-Debt or its related term are showing as below:

GLUE' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.05 Med: 7.99 Max: No Debt
Current: 5.05

During the past 5 years, Monte Rosa Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 5.05. And the median was 7.99.

GLUE's Cash-to-Debt is ranked worse than
54.06% of 1539 companies
in the Biotechnology industry
Industry Median: 6.5 vs GLUE: 5.05

Monte Rosa Therapeutics Cash-to-Debt Historical Data

The historical data trend for Monte Rosa Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Monte Rosa Therapeutics Cash-to-Debt Chart

Monte Rosa Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

7.99

No Debt

5.59

5.05

Monte Rosa Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial												5.59	5.02	4.32	3.85	5.05

Competitive Comparison of Monte Rosa Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Monte Rosa Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Monte Rosa Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Monte Rosa Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Monte Rosa Therapeutics's Cash-to-Debt falls into.

Monte Rosa Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Monte Rosa Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	232.413	/	(3.162	+	42.877)
	=	5.05

Monte Rosa Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	232.413	/	(3.162	+	42.877)
	=	5.05

Monte Rosa Therapeutics (NAS:GLUE) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Monte Rosa Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Monte Rosa Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Monte Rosa Therapeutics (Monte Rosa Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Monte Rosa Therapeutics Inc (NAS:GLUE) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

645 Summer Street, Suite 102, Boston, MA, USA, 02210

Website

https://www.monterosatx.com

Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates.

Executives

Edmund Dunn	officer: Principal Accounting Officer	MONTE ROSA THERAPEUTICS, INC., 321 HARRISON AVENUE, SUITE 900, BOSTON MA 02210
Anthony M. Manning	director	C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Jan Skvarka	director	C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Philip Nickson	officer: General Counsel	MONTE ROSA THERAPEUTICS, INC., 40 GUEST STREET, BOSTON MA 02135
Julian G Jones	officer: Chief Business Officer	MONTE ROSA THERAPEUTICS, INC., 645 SUMMER STREET, SUITE 102, BOSTON MA 02210
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Joshua Makower	10 percent owner	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Paul Edward Walker	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Versant Venture Capital Vi, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Edward T Mathers	10 percent owner	C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Kimberly Blackwell	director	C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Cormorant Private Healthcare Fund Ii, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
New Enterprise Associates 17, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 17, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093